ISOLATION OF PRECURSOR CELLS AND THEIR USE FOR TISSUE REPAIR

• US 20110158960A1
• Filed: 01/03/2011
• Published: 06/30/2011
• Est. Priority Date: 10/06/1999
• Status: Abandoned Application

• Current Assignee: Tigenix NV (Takeda Pharmaceutical Company Limited)
• Original Assignee: Tigenix NV (Takeda Pharmaceutical Company Limited)
• Inventors: DELL'ACCIO, Francesco, LUYTEN, Frank, DE BARI, Cosimo
• Application Number:
  US12/983,658
• Publication Number:
  US 20110158960A1
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61L 27/227 Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
• CPC Class Codes: A61L 27/3804 characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
• CPC Class Codes: A61L 27/3817 Cartilage-forming cells, e.g. pre-chondrocytes
• CPC Class Codes: A61L 27/3843 Connective tissue
• CPC Class Codes: A61L 27/3886 comprising two or more cell types
• CPC Class Codes: A61L 27/3895 using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/04 for non-specific disorders of the connective tissue
• CPC Class Codes: C12N 2501/15 Transforming growth factor beta (TGF-β)
• CPC Class Codes: C12N 2502/1317 Chondrocytes
• CPC Class Codes: C12N 5/0655 Chondrocytes; Cartilage
• CPC Class Codes: C12N 5/0668 Mesenchymal stem cells from other natural sources

Abstract

Cartilage-derived morphogenetic protein CDMP-1 or a transforming growth factor β having at least 80% homology with CDMP-1, or a factor co-expressed and/or co-detectable therewith, is used as a marker of skeletal precursor cells from any part of a mammalian body.

Claims

1. A method for repairing a cartilage defect in a mammal comprising the steps of:

providing an expanded or passaged population of chondrocyte precursor cells isolated from a joint interzone or from bone marrow, and,

implanting said cells into said cartilage defect, thereby repairing said cartilage defect.

2. The method according to claim 1, wherein said joint interzone is periosteum or synovial membrane.

3. The method according to claim 1, further comprising the step of detecting the expression of CDMP-1, or the expression of a gene co-expressed therewith, in said expanded or passaged population of chondrocyte precursor cells.

4. The method according to claim 3, further comprising the step of selecting the cells expressing CDMP-1, or expressing a gene co-expressed therewith.

5. The method according to claim 3, further comprising the step of detecting cells expressing FGFR-3 in said expanded or passaged population of chondrocyte precursor cells.

6. The method according to claim 5, further comprising the step of removing the cells expressing FGFR-3.

7. The method according to claim 1, wherein said chondrocyte precursor cells are co-implanted together with chondrocytes.

8. The method according to claim 1, wherein said chondrocyte precursor cells are administered in a prosthetic device.

9. The method according to claim 1, wherein said cartilage defect is selected from the group consisting of subglottic stenosis, tracheomalacia, chondromalacia patellae, osteoarthritis and traumatic cartilage lesions.

10. The method according to claim 1, further comprising the step of administering a factor that stimulates differentiation of said chondrocyte precursor cells into cartilage.